Cardiol Therapeutics Capital Expenditures (CapEx) Growth & History (CRDL)

Cardiol Therapeutics's capital expenditures (capex) was $24,484 for fiscal 2025.

View full Cardiol Therapeutics company overview

Cardiol Therapeutics annual capital expenditures (capex) history

Cardiol Therapeutics annual capital expenditures (capex)

Fiscal yearPeriod endedCapital expenditures (CapEx)ChangeGrowth
20252025-12-31$24,484$3,194+15.00%
20242024-12-31$21,290−$43,022−66.90%
20232023-12-31$64,312−$10,397−13.92%
20222022-12-31$74,709$61,793+478.42%
20212021-12-31$12,916−$27,686−68.19%
20202020-12-31$40,602

Cardiol Therapeutics capital expenditures (capex) trends

Over the last five fiscal years, Cardiol Therapeutics's capital expenditures (capex) decreased from $40,602 to $24,484, a change of −$16,118. The latest reported quarter, Q2 2026, shows $3,029.

About the metric

What capital expenditures (CapEx) mean

Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.

Calculation and source

SEC-reported capital expenditures

TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Cardiol Therapeutics source filings ↗

Community posts

It’s quiet here.

No posts about CRDL yet. Start the conversation.

Write the first post